Search Results 1101-1110 of 21729 for Inhibition

1. INCB161734 for Advanced or Metastatic Solid Tumors With KRAS G12D Mutation - Mayo Clinic

   Prior treatment with any KRAS G12D inhibitor. Any prior radiation therapy within 28 days before the first dose of study drug. Note: Palliative radiation ...

2. Dermatomyositis Clinical Trials - Mayo Clinic Research

   The purpose of this study is to determine the effetiveness and safety of brepocitinib (a tyrosine kinase [TYK] 2/Janus kinase [JAK] 1 inhibitor) in patients ...

3. Triple-Negative Breast Cancer Clinical Trials - Mayo Clinic Research

   Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of ...

4. Researchers reduce inflammation in human cells, A major cause of frailty - Mayo Clinic News Network

   Senescent cells are cells that contribute to frailty and diseases associated with aging. Also, these same JAK inhibitors reduced inflammatory mediators in mice.

5. Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs - Mayo Clinic

   ... inhibitor ON 01910.Na. Responses occurred in all morphologic, prognostic risk and cytogenetic subgroups, including four patients with marrow complete ...

6. A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene - Mayo Clinic

   Receiving strong CYP3A4 inhibitors/ inducers. Known history of cerebrovascular accident in the past 6 months. Known bleeding diathesis. Known, active ...

7. Innovative therapies shape the future of chronic lymphocytic leukemia treatment - Mayo Clinic

   Then in 2016, the FDA approved the first B-cell lymphoma 2 (BCL-2) inhibitor drug for the disease. BCL-2 inhibitors target BCL-2 proteins that are particularly ...

8. Mayo Clinic Finds Experimental Drug Inhibits Growth in All Stages of Common Kidney Cancer

   The experimental drug, A939572, is a targeted inhibitor of SCD1 protein. "We found it to be incredibly specific to cancer cells in laboratory mice treated ...

9. A Study to Evaluate Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer - Mayo Clinic

   Patients treated with any prior checkpoint inhibitors for metastatic lung cancer are ineligible. ... inhibitors are excluded. Patients with treated brain ...

10. Aspirin Use May Help Prevent Bile Duct Cancer - Mayo Clinic News Network

    “Aspirin, with it's an anti-inflammatory properties, may reduce the risk of bile duct cancer by lessening inflammation through inhibition of an enzyme ...